KalVista appoints William Fairey to Board; commercial expertise in rare disease

KalVista Pharmaceuticals, Inc.

William Fairey appointed to Board effective April 18, 2024 as Class III director.
Mr. Fairey previously served as Chief Commercial Officer at MyoKardia and COO at ChemoCentryx.
Initial compensation includes options to purchase 17,000 shares and $42,500 annual cash retainer.
Appointment adds commercial launch experience ahead of planned FDA submission for sebetralstat.
Mr. Fairey is independent under Nasdaq and SEC rules.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

William Fairey

Class III Director

KALV · KalVista Pharmaceuticals, Inc.

Effective: 2024-04-18
Filed: April 22, 2024, 7:59 PM ET

the Board approved the appointment of William Fairey (“ Mr. Fairey ”) to the Board effective immediately, to serve until his successor is duly elected and qualified

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

William Fairey was appointed as Class III Director at KalVista Pharmaceuticals, Inc..

Action: appointed
Role: Class III Director

Exact text from the filing

the Board approved the appointment of William Fairey (“ Mr. Fairey ”) to the Board effective immediately, to serve until his successor is duly elected and qualified

View on SEC.gov

KalVista Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-046481

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.